Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 5/20 | 0.44 |
| ▸ | SLC6A11 | P48066 | 5/20 | 0.44 |
| ▸ | SLC6A13 | Q9NSD5 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.41 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15616801 | 1.00 | SLC6A12 (0.44) | SLC6A12SLC6A11SLC6A13CA1CA2 | |
| SCHEMBL9294224 | 1.00 | SLC6A12 (0.44) | SLC6A12SLC6A11SLC6A13CA1CA2 | |
| SCHEMBL4120941 | 1.00 | SLC6A12 (0.44) | SLC6A12SLC6A11SLC6A13CA1CA2 | |
| SCHEMBL4120944 | 1.00 | SLC6A12 (0.44) | SLC6A12SLC6A11SLC6A13CA1CA2 | |
| SCHEMBL4112859 | 0.95 | CA1 (0.46) | SLC6A12SLC6A11SLC6A13CA1CA2 | |
| SCHEMBL7323358 | 0.95 | CA1 (0.46) | SLC6A12SLC6A11SLC6A13CA1CA2 | |
| SCHEMBL4112861 | 0.95 | CA1 (0.46) | SLC6A12SLC6A11SLC6A13CA1CA2 | |
| SCHEMBL19336874 | 0.95 | CA1 (0.46) | SLC6A12SLC6A11SLC6A13CA1CA2 | |
| SCHEMBL4127933 | 0.95 | CA1 (0.46) | SLC6A12SLC6A11SLC6A13CA1CA2 | |
| SCHEMBL4112857 | 0.95 | CA1 (0.46) | SLC6A12SLC6A11SLC6A13CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3852746-A1 | CYCLOPENTYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020060915-A1 | CYCLOPENTYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20050215541-A1 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ATHENA NEUROSCIENCES, INC. AND ELI LILLY & COMPANY | 2005-09-29 | — | — | US | disclosed |
| EP-1173170-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1173170-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000059503-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| US-5376618-A | Receiver layer contains copolyester from diols, dicarboxylic acids and long chain alkyl hydroxy-carboxylic acids | AGFA-GEVAERT, N.V. (BE) | 1994-12-27 | — | — | US | disclosed |
| EP-0481130-B1 | Thermal dye sublimation transfer receiving element | AGFA GEVAERT NV (BE) | 1994-06-08 | — | — | EP | disclosed |
| EP-0481130-A1 | Thermal dye sublimation transfer receiving element | AGFA-GEVAERT N.V. (BE) | 1992-04-22 | — | — | EP | disclosed |
| US-4792550-A | THROMBOXANE ANTAGONIST-HYPOTENSIVE AGENT; CARDIOVASCULAR, NERVOUS SYSTEM DISORDERS; ANTIALLERGENS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-20 | — | — | US | disclosed |
| EP-0171146-B1 | 13-AZA-14-OXO-TXA2 ANALOGUES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-09-28 | — | — | EP | disclosed |
| EP-0171146-A1 | 13-Aza-14-oxo-txa2 analogues | ONO PHARMACEUTICAL CO., LTD. (JP) | 1986-02-12 | — | — | EP | disclosed |
| US-4277403-A | Prostaglandin intermediates | PFIZER INC. (US) | 1981-07-07 | — | — | US | disclosed |
| US-4277403-A | Prostaglandin intermediates | PFIZER INC. (US) | 1981-07-07 | — | — | US | disclosed |
| US-4213907-A | Prostaglandin intermediates | PFIZER INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4213907-A | Prostaglandin intermediates | PFIZER INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4018797-A | Intermediates for prostaglandins | THE DOW CHEMICAL COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | SLC6A12 2207/4885SLC6A11 179/4885SLC6A13 239/4885 |
| US-20050215541-A1 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | BACE1, APP, BACE2 | SLC6A12 3505/4885SLC6A11 2399/4885SLC6A13 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.